Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYGEN vs ACTAHIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
No approved medical indications (Schedule I controlled substance in US),Investigational use in psychotherapy for anxiety, depression, and addiction (off-label)
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
For adults, administer 500 mg orally twice daily with or without food.
1.34 mg (one capsule) orally twice daily.
12 hours; prolonged to 24 hours in severe renal impairment (Cr Cl <30 m L/min)
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Primarily hepatic via CYP450 enzymes, including CYP3A4 and CYP2D6; undergoes N-demethylation, N-deethylation, and hydroxylation.
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Renal (90% as unchanged drug), biliary/fecal (10%)
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
85% bound to albumin
92% bound to albumin.
1.5 L/kg (reflects extensive tissue distribution)
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
Oral: 70-80% (first-pass metabolism reduces from 90% intrinsic absorption)
Oral: 68% ± 12% due to first-pass metabolism.
For GFR 30-89 m L/min: 500 mg orally once daily. For GFR <30 m L/min or on hemodialysis: 250 mg orally once daily. Administer after dialysis on dialysis days.
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
Child-Pugh A and B: No adjustment necessary. Child-Pugh C: Contraindicated; do not use.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
For children 2-12 years: 10 mg/kg orally twice daily; maximum 500 mg per dose. For children 12-18 years: Administer as adult dose.
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
Initiate at 250 mg orally twice daily for patients ≥65 years. Titrate to 500 mg twice daily as tolerated. Monitor renal function closely.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
Not applicable; no FDA-approved indications and no FDA boxed warnings exist for LSD.
None.
Risk of severe psychological distress, prolonged psychosis, hallucinogen persisting perception disorder (HPPD), and suicide.,May exacerbate psychiatric conditions; use only under strict medical supervision in research settings.,Potential for serotonin syndrome when combined with serotonergic drugs.
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
History of schizophrenia or psychotic disorder,Severe cardiovascular disease,Uncontrolled hypertension,Pregnancy and breastfeeding,Concurrent use with MAOIs or other serotonergic drugs
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
No specific food interactions are documented for LYGEN. It can be taken with or without food. However, grapefruit juice may theoretically affect CYP3A4 metabolism, but clinical significance is minimal. Alcohol should be avoided due to additive CNS depression.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
No human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: avoid unless benefit outweighs risk; second/third trimester: limited data, use caution.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
No data on excretion in human milk; M/P ratio unknown; caution in breastfeeding women due to potential for adverse effects in nursing infants.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
No established dosing adjustments; pharmacokinetics may be altered, requiring therapeutic drug monitoring if applicable; consult specialist for individualized dosing.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
LYGEN (lacosamide) is a third-generation antiepileptic drug that selectively enhances slow inactivation of voltage-gated sodium channels. Key pearls: 1) Titrate slowly (50 mg BID weekly) to minimize CNS side effects like dizziness and ataxia. 2) Dose adjustment needed for Cr Cl <30 m L/min (max 300 mg/day). 3) Can cause PR interval prolongation; avoid in patients with second- or third-degree AV block. 4) Contraindicated in severe hepatic impairment (Child-Pugh C). 5) Available as oral tablets, oral solution, and IV; IV to oral conversion 1:1.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
Take LYGEN exactly as prescribed; do not suddenly stop taking it without talking to your doctor, as this can increase seizure frequency.,You may experience dizziness or blurred vision, especially at the start of treatment; avoid driving or operating heavy machinery until you know how the medication affects you.,LYGEN can cause a slow heart rate or fainting; tell your doctor if you have a history of heart problems or if you feel your heart beating slowly or irregularly.,Do not drink alcohol while taking LYGEN, as it may worsen side effects like drowsiness and dizziness.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits with your doctor.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYGEN vs ACTAHIST, answered by our medical review team.
LYGEN is a Estrogen that works by Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.. ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYGEN and ACTAHIST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYGEN is: For adults, administer 500 mg orally twice daily with or without food.. The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYGEN and ACTAHIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYGEN is classified as Category C. No human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: avoid unless benefit outweighs risk; second/third trimester: limited data, . ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.